Cellmid Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.061|
|52 Week High||AU$0.049|
|52 Week Low||AU$0.14|
|1 Month Change||15.09%|
|3 Month Change||1.67%|
|1 Year Change||-41.90%|
|3 Year Change||-83.29%|
|5 Year Change||-91.29%|
|Change since IPO||-98.44%|
Recent News & Updates
|CDY||AU Personal Products||AU Market|
Return vs Industry: CDY underperformed the Australian Personal Products industry which returned 17% over the past year.
Return vs Market: CDY underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: CDY is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CDY's weekly volatility (9%) has been stable over the past year.
About the Company
Cellmid Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan. It develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company markets its products through retailers and wholesalers, as well as through a direct-to-consumer, e-commerce platform.
Cellmid Fundamentals Summary
|CDY fundamental statistics|
Is CDY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CDY income statement (TTM)|
|Cost of Revenue||AU$2.11m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.02|
|Net Profit Margin||-65.42%|
How did CDY perform over the long term?See historical performance and comparison
Is Cellmid undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CDY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CDY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CDY is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.
PE vs Market: CDY is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDY is good value based on its PB Ratio (1.1x) compared to the AU Personal Products industry average (2.9x).
How is Cellmid forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CDY's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if CDY's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CDY's revenue (29.9% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: CDY's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDY's Return on Equity is forecast to be high in 3 years time
How has Cellmid performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDY is currently unprofitable.
Growing Profit Margin: CDY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDY is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare CDY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDY is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).
Return on Equity
High ROE: CDY has a negative Return on Equity (-36.47%), as it is currently unprofitable.
How is Cellmid's financial position?
Financial Position Analysis
Short Term Liabilities: CDY's short term assets (A$11.3M) exceed its short term liabilities (A$1.9M).
Long Term Liabilities: CDY's short term assets (A$11.3M) exceed its long term liabilities (A$943.5K).
Debt to Equity History and Analysis
Debt Level: CDY's debt to equity ratio (9%) is considered satisfactory.
Reducing Debt: CDY's debt to equity ratio has reduced from 21.2% to 9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CDY has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 6.9% each year.
What is Cellmid current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDY's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Maria Halasz, MBA, BSc, has been the Chief Executive Officer of Cellmid Limited since April 14, 2007 and has been its Managing Director since November 2007. Ms. Halasz served as Managing Director of Ce...
CEO Compensation Analysis
Compensation vs Market: Maria's total compensation ($USD429.90K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.
Experienced Management: CDY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: CDY's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CDY insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.6%.
Cellmid Limited's employee growth, exchange listings and data sources
- Name: Cellmid Limited
- Ticker: CDY
- Exchange: ASX
- Founded: 2004
- Industry: Personal Products
- Sector: Household
- Market Cap: AU$11.433m
- Shares outstanding: 187.43m
- Website: https://cellmid.com.au
- Cellmid Limited
- 55 Clarence Street
- Suite 204
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:02|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.